DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
This week the FDA approved a novel treatment for sickle cell disease, a serious and sometimes deadly disease that affects around 100,000 Americans. The treatment was found to exceptionally improve the health and quality of life in the “end of life” patients involved in the trials, and experts believe that upon release, it may do much to improve the lives of sickle cell patients throughout the world.
Oxbryta is an inhibitor of deoxygenated sickle hemoglobin polymerization and was granted Accelerated Approval. This classification allows the FDA to quickly approve drugs for serious conditions. The drug’s trial consisted of 274 patients with sickle cell disease who received different doses of the medication or a placebo, a press release explained.
Results showed that the medication was able to increase the hemoglobin response rate in patients far more than those in the placebo group. This is important as sickle cell affects the hemoglobin, a type of red blood cell, and leads to some of the disease’s devastating effects.
news & eventsA new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
news & eventsIn France, Boy Becomes First Sickle Cell Disease Patient to be Treated With Gene TherapyA 13-year-old boy with sickle cell disea...
education & researchDoes sickle cell disease increase risk of adverse outcomes following total hip and knee arthroplasty? A nationwide d...Sickle cell disease (SCD) is associated ...
news & eventsToronto Neuroscientist Getting Closer to Tailored Treatments for Chronic PainDaily tasks most people don't think too ...
Community CenterToday’s Faces of Sickle Cell Disease: Courtney Fitzhugh, M.D.Courtney Fitzhugh first became intereste...
news & eventsNew Guidelines for Managing Sickle Cell Disease Presented at ACP Internal Medicine MeetingNew guidelines for therapeutic strategie...
news & eventsSolution to 50-year-old mystery could lead to gene therapy for common blood disordersIn a landmark study that could lead to n...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.